Table 4.
Metformin plasmatic concentrations among DMT2 patients grouped by SNP and genotype.
| Gene | SNP | Genotype | Control (ng/mL) Median (IQR 25–75%) (n) |
Non-Control (ng/mL) Median (IQR 25–75%) (n) |
* p = |
|---|---|---|---|---|---|
|
SLC22A1 (OCT1) |
rs72552763 | GAT/GAT | 376.9 (133.4–763) (17) | 481.7 (185.9–971) (17) | 0.812 |
| del/GAT | 137.1 (66.47 687.4) (14) | 790.6 (228.8–1030.2) (27) | 0.115 | ||
| del/del | 139.1 (107.6–264.3) (6) | 785.6 (70.2–1642.7) (5) | 0.792 | ||
| * p = | 0.358 | 0.820 | |||
| rs622342 | A/A | 339.7 (129.8–700.9) (16) | 526.3 (169–1000.9) (16) | 0.616 | |
| A/C | 102.6 (57.2–737.7) (12) | 725 (254.5–969) (23) | 0.141 | ||
| C/C | 157.8 (132.1–687.4) (9) | 795.4 (70.2–1642.7) (10) | 0.604 | ||
| * p = | 0.381 | 0.821 | |||
|
SLCA22A2 (OCT2) |
rs316019 | C/C | 151.9 (105.2–687.4) (34) | 648.2 (183.3–1030.9) (46) | 0.098 |
| A/C | 302.5 (283.4–589.5) (3) | 804 (507.4–1025.8) (3) | 0.827 | ||
| A/A | (0) | (0) | - | ||
| * p = | 0.373 | 0.646 | |||
|
SLC22A3 (OCT3) |
rs2076828 | C/C | 144.3 (105.2–763) (30) | 685.7 (126.9–1030.2) (35) | 0.286 |
| C/G | 320.6 (157.8–618.8) (6) | 611 (386.1–880.8) (11) | 0.122 | ||
| G/G | 1321.6 (1) | 1030.9 (723.9–1336.8) (3) | - | ||
| * p = | 0.734 | 0.634 | |||
| ABCB1 | rs1128503 | C/C | 763 (264.3–1321.6) (9) | 526.3 (146–1004.7) (14) | 0.450 |
| C/T | 139.8 (90.3–649.7) (16) | 844.7 (481.7–1095.1) (22) | 0.011 * | ||
| T/T | 150.1 (113.9–402.6) (12) | 219.8 (70.2–530.7) (13) | 0.624 | ||
| * p = | 0.233 | 0.066 | |||
| rs2032582 | G/G | 496.5 (107.6–815) (13) | 788.1 (146–1055.6) (16) | 0.539 | |
| G/T | 181.1 (118.2–768.5) (17) | 491.4 (185.9–884.2) (18) | 0.041 * | ||
| T/T | 526.3 (142.5–752.7) (6) | 210.8 (72.9–869.7) (9) | 0.955 | ||
| T/A | (0) | 2286 (1348.7–3223.2) (2) | - | ||
| G/A | 105.2 (1) | 428.9 (199.6–1158.2) (3) | - | ||
| * p = | 0.584 | 0.733 | |||
| rs1045642 | C/C | 700.9 (133.4–1321.6) (10) | 785.6 (233.3–1017.8) (19) | 0.891 | |
| C/T | 116.3 (85.7–157.8) (17) ¥ | 530.7 (185.9–1095.1) (21) | 0.002 * | ||
| T/T | 414.4 (264.3–876.5) (10) | 290.5 (72.9–901.4) (9) | 0.568 | ||
| * p = | 0.014 κ | 0.692 | |||
| CYP2C9 | rs1799853 (*2) rs1057910 (*3) | *1/*1 | 200.68 (111.5–815) (29) | 725 (210.8–1030.9) (41) | 0.222 |
| *1/*2 | 278.9 (92.9–481.5) (7) | 107.8 (89–126.9) (3) | 0.425 | ||
| *2/*2 | (0) | (0) | - | ||
| *1/*3 | 157.85 (1) | 712.3 (376.7–2078.2) (4) | - | ||
| *2/*3 | (0) | 1705.38 (1) | - | ||
| *3/*3 | (0) | (0) | - | ||
| * p = | 0.753 | 0.077 | |||
| rs1934969 | A/A | 151.9 (106.4–649.7) (24) | 530.7 (210.8–1088.9) (33) | 0.051 | |
| A/T | 451.6 (80.5–1321.3) (10) | 785.6 (290.5–971) (13) | 0.620 | ||
| T/T | 133.4 (122.5–474.2) (3) | 22.817 (15.9–539.2) (3) | 0.513 | ||
| * p = | 0.770 | 0.374 |
* Mann–Whitney U-test < 0.05. κ p < 0.05 for Kruskal–Wallis test. ¥ p < 0.05 for post-hoc test between genotypes.